JP2023553534A5 - - Google Patents
Info
- Publication number
- JP2023553534A5 JP2023553534A5 JP2023560241A JP2023560241A JP2023553534A5 JP 2023553534 A5 JP2023553534 A5 JP 2023553534A5 JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023560241 A JP2023560241 A JP 2023560241A JP 2023553534 A5 JP2023553534 A5 JP 2023553534A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063124669P | 2020-12-11 | 2020-12-11 | |
| US63/124,669 | 2020-12-11 | ||
| US202163214736P | 2021-06-24 | 2021-06-24 | |
| US63/214,736 | 2021-06-24 | ||
| US202163277555P | 2021-11-09 | 2021-11-09 | |
| US63/277,555 | 2021-11-09 | ||
| US202163283035P | 2021-11-24 | 2021-11-24 | |
| US63/283,035 | 2021-11-24 | ||
| PCT/US2021/062927 WO2022125971A1 (en) | 2020-12-11 | 2021-12-10 | Combination therapies for the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023553534A JP2023553534A (ja) | 2023-12-21 |
| JPWO2022125971A5 JPWO2022125971A5 (https=) | 2024-12-17 |
| JP2023553534A5 true JP2023553534A5 (https=) | 2024-12-17 |
Family
ID=81974015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560241A Pending JP2023553534A (ja) | 2020-12-11 | 2021-12-10 | 癌の処置のための併用療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20250195533A1 (https=) |
| EP (1) | EP4259639A4 (https=) |
| JP (1) | JP2023553534A (https=) |
| KR (1) | KR20230151981A (https=) |
| AU (1) | AU2021397319A1 (https=) |
| CA (1) | CA3201612A1 (https=) |
| WO (1) | WO2022125971A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12122787B2 (en) | 2019-09-20 | 2024-10-22 | Shanghai Jemincare Pharmaceuticals Co., Ltd | Fused pyridone compound, and preparation method therefor and use thereof |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
| WO2023059771A1 (en) * | 2021-10-06 | 2023-04-13 | Erasca, Inc. | Uses of tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
| PL4426303T3 (pl) * | 2021-11-02 | 2026-02-09 | Semmelweis Egyetem | Inhibitory transferazy farnezylowej i inhibitory kras do leczenia nowotworów z mutacją kras |
| PE20251110A1 (es) * | 2022-08-19 | 2025-04-22 | Mirati Therapeutics Inc | Composiciones farmaceuticas solidas de adagrasib |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9670231B2 (en) * | 2013-06-28 | 2017-06-06 | Beigene, Ltd. | Fused tricyclic amide compounds as multiple kinase inhibitors |
| EA201992781A1 (ru) * | 2017-05-22 | 2020-04-01 | Эмджен Инк. | Ингибиторы g12c kras и способы их применения |
| JP7542538B2 (ja) * | 2018-09-18 | 2024-08-30 | ニカング セラピューティクス， インコーポレイテッド | Ｓｒｃホモロジー－２ホスファターゼ阻害剤としての縮合三環式環誘導体 |
| JP7377679B2 (ja) * | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | がん治療のためのｋｒａｓｇ１２ｃ阻害剤及び１種以上の薬学的に活性な追加の薬剤を含む併用療法 |
| CN113164418A (zh) * | 2018-12-05 | 2021-07-23 | 米拉蒂治疗股份有限公司 | 组合疗法 |
| WO2020165732A1 (en) * | 2019-02-12 | 2020-08-20 | Novartis Ag | Pharmaceutical combination comprising tno155 and a krasg12c inhibitor |
| JP2023553533A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| JP2023553532A (ja) * | 2020-12-11 | 2023-12-21 | エラスカ，インク． | 癌の処置のための併用療法 |
| US20240293422A1 (en) * | 2021-06-24 | 2024-09-05 | Erasca, Inc. | Shp2 and cdk4/6 inhibitors combination therapies for the treatment of cancer |
-
2021
- 2021-12-10 WO PCT/US2021/062927 patent/WO2022125971A1/en not_active Ceased
- 2021-12-10 CA CA3201612A patent/CA3201612A1/en active Pending
- 2021-12-10 AU AU2021397319A patent/AU2021397319A1/en not_active Abandoned
- 2021-12-10 EP EP21904514.3A patent/EP4259639A4/en not_active Withdrawn
- 2021-12-10 KR KR1020237023425A patent/KR20230151981A/ko not_active Abandoned
- 2021-12-10 US US18/256,091 patent/US20250195533A1/en active Pending
- 2021-12-10 JP JP2023560241A patent/JP2023553534A/ja active Pending